Mulberrofuran G
Based on 1 publication(s) in Google Scholar
Mulberrofuran G is a NOX inhibitor (IC50: 6.9 μM) and tyrosinase inhibitor. Mulberrofuran G exhibits anti-inflammatory, antioxidant, antiviral, antitumor, and neuroprotective effects. Mulberrofuran G can be used in the research of tumors, nervous system diseases, and other conditions.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.86%
- CAS No.: 87085-00-5
- Formule: C34H26O8
- Masse moléculaire:562.57
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Mulberrofuran G
MoreVoir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
|
NOX4 |
JAK2 |
STAT3 |
Caspase 3 |
Caspase-9 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hep 3B2 | IC50 |
>30 μM
Compound: 6
|
Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay
Inhibition of hypoxia-induced HIF1 activation in human Hep3B cells by pGL3-HRE-luciferase reporter gene assay
|
[PMID: 19072214] |
| Hep 3B2 | IC50 |
2.6 μM
Compound: 6
|
Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis
Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis
|
[PMID: 19072214] |
| Hep 3B2 | IC50 |
28.6 μM
Compound: 6
|
Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA
Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA
|
[PMID: 19072214] |
| Platelet | IC50 |
1.07 x 10-5 M
Compound: Mulberrofuran G
|
Inhibition of 12-hydroxy-5,8,10-heptadecatrienoic acid formation in Wistar King platelets
Inhibition of 12-hydroxy-5,8,10-heptadecatrienoic acid formation in Wistar King platelets
|
[PMID: 3097265] |
| Platelet | IC50 |
3.47 x 10-5 M
Compound: Mulberrofuran G
|
Inhibition of thromboxane B2 formation in Wistar King platelets
Inhibition of thromboxane B2 formation in Wistar King platelets
|
[PMID: 3097265] |
| Platelet | IC50 |
8.9 x 10-5 M
Compound: Mulberrofuran G
|
Inhibition of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets
Inhibition of 12-hydroxy-5,8,10,14-eicosatetraenoic acid formation in Wistar King platelets
|
[PMID: 3097265] |
Mulberrofuran G (0.89-909.42 μM) inhibits HBV DNA replication in HepG 2.2.15 cells with an IC50 of 3.99 μM, and exhibits cytotoxicity to HepG 2.2.15 cells with a CC50 of 8.04 μM[1].
Mulberrofuran G (1-100 μM; 24 h) significantly suppresses cell proliferation, migration, and invasion in A549 and NCI-H226 cells, with the mechanism involving the inhibition of the JAK2/STAT3 pathway[2].
Mulberrofuran G (0-3 μM; 24 h) potently inhibits the infection of SARS-CoV-2 (βCoV/Korea/KCDC03/2020) in Vero cells, with an IC50 of 1.55 μM[3].
Mulberrofuran G (0.016-2 μM; 4-40 h) enhances cell viability, suppresses ROS production and apoptotic signals, and alleviates ER stress in oxygen-glucose deprivation/reoxygenation-treated SH-SY5Y cells. The mechanism is associated with the inhibition of NOX4[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells and NCIH226 cells
-
Concentration:1, 5, 10 and 100 μM
-
Incubation Time:24 h
-
Result:Significantly inhibited the proliferation of lung cancer cells with IC50 values of 22.5 μM and 30.6 μM for A549 cells and NCIH226 cells, respectively.
-
Cell Line:SH-SY5Y cells treated oxygen-glucose deprivation/reoxygenation (OGD/R)
-
Concentration:0.08, 0.4, and 2 μM
-
Incubation Time:40 h
-
Result:Inhibited the levels of cleaved caspase-9, caspase-3, and PARP.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Sprague-Dawley rats (230-240 g) with middle cerebral artery occlusion/reperfusion (MCAO/R)[4]
-
Dosage:0.2, 1 and 5 mg/kg
-
Administration:Intraperitoneal injection; single dose; 30 min before operation
-
Result:Significantly decreased the infarct volume in a dose-dependent manner, with the infarct volumes of 0.2, 1, and 5 mg/kg groups being 39.0%, 26.0%, and 19.0% respectively, compared to 51.2% in the vehicle group.
Downregulated the protein expression of NOX4, GRP78/BiP, p-IRE1α, XBP1, and CHOP in the ischemic brain tissue.
Chemical Information
-
CAS No. 87085-00-5
-
Appearance Solid
-
Masse moléculaire 562.57
-
Formule C34H26O8
-
Color White to off-white
-
SMILES
OC1=C(C=CC(O)=C1)[C@]23[C@]4([H])[C@](C=C(C)C[C@@]4([H])C5=C(C=C(O)C=C5)O3)([H])C6=C(O)C=C(C7=CC8=C(C=C(O)C=C8)O7)C=C6O2
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Talanta
A targeted strategy for screening bioactive inhibitors from Morus alba L.: Immobilized PTP1B affinity chromatography. [Abstract]2026 Sep 1:307:129772. PMID: 41955787
Solvant et solubilité
DMSO : 50 mg/mL (88.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.22 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.22 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Geng CA, et al. Mulberrofuran G and isomulberrofuran G from Morus alba L.: anti-hepatitis B virus activity and mass spectrometric fragmentation. J Agric Food Chem. 2012;60(33):8197-8202. [Content Brief]
[3]. Kim YS, et al. Mulberrofuran G, a Mulberry Component, Prevents SARS-CoV-2 Infection by Blocking the Interaction between SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor. Nutrients. 2022 Oct 7;14(19):4170. [Content Brief]
[4]. Hong S, et al. Mulberrofuran G Protects Ischemic Injury-induced Cell Death via Inhibition of NOX4-mediated ROS Generation and ER Stress. Phytother Res. 2017;31(2):321-329. [Content Brief]
[5]. Koirala P, et al. Structure⁻Activity Relationship of the Tyrosinase Inhibitors Kuwanon G, Mulberrofuran G, and Albanol B from Morus Species: A Kinetics and Molecular Docking Study. Molecules. 2018 Jun 11;23(6):1413. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7776 mL | 8.8878 mL | 17.7756 mL | 44.4389 mL |
| 5 mM | 0.3555 mL | 1.7776 mL | 3.5551 mL | 8.8878 mL | |
| 10 mM | 0.1778 mL | 0.8888 mL | 1.7776 mL | 4.4439 mL | |
| 15 mM | 0.1185 mL | 0.5925 mL | 1.1850 mL | 2.9626 mL | |
| 20 mM | 0.0889 mL | 0.4444 mL | 0.8888 mL | 2.2219 mL | |
| 25 mM | 0.0711 mL | 0.3555 mL | 0.7110 mL | 1.7776 mL | |
| 30 mM | 0.0593 mL | 0.2963 mL | 0.5925 mL | 1.4813 mL | |
| 40 mM | 0.0444 mL | 0.2222 mL | 0.4444 mL | 1.1110 mL | |
| 50 mM | 0.0356 mL | 0.1778 mL | 0.3555 mL | 0.8888 mL | |
| 60 mM | 0.0296 mL | 0.1481 mL | 0.2963 mL | 0.7406 mL | |
| 80 mM | 0.0222 mL | 0.1111 mL | 0.2222 mL | 0.5555 mL |
Mulberrofuran G Related Classifications
HY-N3239 Related Classifications
Powered by Bioz